Drug intelligence / Profile preview

collismycin analog

Development stage: Preclinical
Lead developer: EntreChem
Modality: Small Molecules

Overview

Collismycin analog is a small molecule natural product analog being developed by EntreChem for the treatment of conditions requiring immunosuppression. The compound is derived from the collismycin family, which are 2,2'-bipyridine natural products typically isolated from *Streptomyces* bacteria. EntreChem utilizes its proprietary combinatorial biosynthesis and genetic engineering platform to modify the biosynthetic pathways of these natural products, creating novel analogs with optimized pharmacological properties. Currently in the early preclinical stage, this analog is reported to target NRP5, although specific details regarding its molecular mechanism of action in immune modulation remain limited.

Targets

LRP5 (Low-density lipoprotein receptor-related protein 5)

Beyond the preview

Go deeper on collismycin analog.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on collismycin analog.

Explore the full profile